The Cancer Drug Development Forum (CDDF) shared on LinkedIn:
“We are delighted to open the CDDF and EORTC Joint Workshop on ‘Health Technology Assessment in Cancer Drug Development’ in Brussels today.
We welcome all attendees to this unique, multi-stakeholder meeting where open, constructive discussion will take place for the next two days.
Check out today’s program and the speakers joining us:
‘Session 1: Setting the scene: HTA landscape and societal needs‘ will discuss where HTA currently stands in cancer drug development, the perspectives and challenges of the different stakeholders, and some key questions looking ahead.
Chairs and speakers: Denis Lacombe (EORTC), Gerry Feeney (Patient Advocate), Roisin Adams (NCPE), Yannis Natsis (ESIP; MEDEV), Gabe Sonke (Netherlands Cancer Institute) and Lara J Wolfson (MSD).
‘Session 2:Implementation of HTA regulation: Practical learnings‘ will bring together a diverse group of stakeholders to share their practical insights gained from the implementation of the HTA regulation.
Chairs and speakers: Maddalena Malerba (BMS), Beate Wieseler (IQWIG), Maya Matthews (European Commission), Maria Nieto-Gutierrez (AstraZeneca), Carole Longson (Carole Longson Consultancy), Joséphine Mosset-Keane (Cancer Patients Europe), Mojca Unk (Institute of Oncology Ljubljana).
‘Session 3: HTA regulation and methodological foundations’ will deep dive into the HTA methodological framework, HTA Regulation, key evidence-generation concepts and the integration of patient-relevant outcomes and patient involvement in HTA and regulatory decision-making.
Session chairs and speakers: Sacha Wissink (MSD), Oriol Solà-Morales (Fundació HiTT), Sara Couto (National Authority of Medicines and Health Products), Kristel Vandormael (MSD), Aris Angelis (Chair, Greek HTA Committee and Advisor to the Minister of Health).
We look forward to today’s insightful discussions and open debate with multi-stakeholder audiences and speakers. Stay tuned for more updates!”
To which EORTC – European Organisation for Research and Treatment of Cancer added:
“EORTC is proud to contribute to the workshop, with Denis Lacombe, EORTC CEO, serving as Programme Co-Chair and Chair of key discussions exploring the implementation of the EU HTA Regulation and its implications for the future of cancer drug development.
Over the next two days, participants will address topics ranging from methodological foundations for HTA to future innovations in precision medicine, advanced therapies, artificial intelligence and digital health.”
Other articles about CDDF on OncoDaily.